ClinicalTrials.gg
RecruitingNCT06988644PSYTaBUpdated May 29, 2025

Impact of a Counseling Consultation in the Workplace for Smoker Health Professionals

An interventional study of exhaled carbon monoxyde measurement in Smoking Cessation, sponsored by Groupe Hospitalier Mutualiste de Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Groupe Hospitalier Mutualiste de Grenoble · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2024, registered May 2025).
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Smoking Cessation with a site in France — 8 open to participants now, 11 under way, 1 of them phase 3. Smoking Cessation · France.

Planned enrollment
35th of 43
30 · median 124
Started
2024
with 1 other
No phase
21 of 48
7 open now
Primary completion
2026-11
later than 4 of 10 live
Registered
45th of 48
by date
Lead sponsor
2 of 48
Groupe Hospitalier Mutualiste de Grenoble

Among the 48 studies in Smoking Cessation with a site in France, this one is the 35th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2024, is one of 21 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 45th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

8 of the 48 studies in Smoking Cessation with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Smoking Cessation with a site in France, or all of them as a file.
02

Study summary

Smoking is still a major cause of premature death in France (75,000 deaths a year). Health professionals also seem to be affected by smoking, but few studies have been carried out on this population of smokers. While having a job can be protective, certain working conditions are at risk: night shifts, stress, physical strain, burnout... In 2010, 23% of nurses and 40% of nursing auxiliaries were smokers. More recently, a study of 10,000 health professionals in a French health establishment in 2022 revealed a rate of 32% among nursing auxiliaries.

Data on smoking among health professionals is still scarce. Yet they seem essential, given that smoking among healthcare professionals seems to be an obstacle to dealing with patients' consumption and contributes to the erroneous representations that persist in psychiatry more than elsewhere, such as: "smoking with a patient makes an alliance with them", "smoking is a way of reducing psychological tension", "patients have other problems to deal with", "it won't work because they've been smoking for years". Smoking in mental health facilities is high among both patients and professionals.

Investigators now know that smoking has an impact on mood disorders and sleep. It aggravates all somatic and psychological pathologies and predisposes people to more diabetes, chronic bronchitis, cardiovascular disease, cancer, etc. It also interacts with many drugs.

Smoking screening and cessation assistance have become an indicator of quality somatic care in mental health institutions.

Investigators hypothesise that a consultation in the workplace can help employees to change their smoking habits.

The aims of this study are to assess the effect of a workplace smoking clinic on smokers employed in a mental health institution, and to describe their smoking habits and profiles according to occupational category, with a view to implementing appropriate preventive and treatment measures.

Read the detailed description

Smoking is still a major cause of premature death in France (75,000 deaths a year). Healthcare professionals also seem to be affected by smoking, and few studies have been carried out on this population of smokers.

In 2010, 23% of nurses and 40% of nursing auxiliaries in France said they smoked every day. In a more recent study on parisian hospitals, the prevalence of daily smoking was observed among 26.8% of nurse auxiliaries, 26.3% of nurses, 16.7% of physiotherapists, 27.6% of health managers and 27% of doctors. Among the 3,659 respondents to a study at the Hospices Civils de Lyon, the smoking rate among paramedics (nurses, nursing auxiliaries, and health managers) was 25.6%. Among doctors, pharmacists and dentists, the proportion of smokers is 17.3%, while it reaches 46% among technical and logistics staff. The same survey also showed that paramedical students are three times more likely to be smokers than medical students, and that night staff are 1.5 times more likely to be smokers, given the same age.

In mental health establishments, smoking is prevalent among both patients and healthcare professionals. Investigators now know that smoking affects mood and sleep. It aggravates all pathologies (somatic and psychological) and predisposes people to more diabetes, chronic bronchitis, cardiovascular disease, cancer, etc. It interacts with many psychotropic and analgesic drugs. Smoking screening and cessation assistance have become a quality of care indicator in mental health institutions.

Investigators hypothesise that easier access to smoking cessation consultations in the workplace will improve uptake of this support and encourage smoker carers to change their smoking habits, and that experimenting with this support will increase smoker carers' confidence in their ability to manage their patients' smoking.

The issue of smoking in patients with psychiatric comorbidity is a major one. Smoking significantly reduces their life expectancy: an average of 25 years less, compared with 10 years for smokers without mental disorders. Cardiovascular disease and cancer are the leading causes of premature death. Smoking also affects their quality of life by increasing their metabolic risk (diabetes), reducing their respiratory capacity (chronic obstructive bronchitis) and increasing their risk of chronic disabling pain (arteritis of the lower limbs). Healthcare professionals are expected to play an active role in the fight against smoking and to act as role models for those receiving care, promoting appropriate lifestyles to maintain good health.

Smoking by health professionals does not appear to be more prevalent at the Centre Hospitalier Alpes-Isère than in the general population: 25.9% compared with 25.5%, but this is still significant and probably contributes to the erroneous representations of smoking in psychiatry.

Today, the recommendations of the Haute Autorité de Santé specify that psychological support and assistance are the basis of treatment. Nicotine substitutes supplement this support if the smoker shows signs of nicotine dependence. For smoker health professionals, the offer of smoking counselling in the workplace is likely to encourage them to use these aids and to succeed.

In previous studies, investigators found cessation rates at 12 months of 33% in an intensive intervention group (NST, intensive advice and outpatient telephone follow-up) compared with 20% in a control group (minimal advice) (RR = 1.7; 95% CI: 1.1 to 2.7).

In a study of hospital smoking clinics, 29.5% of patients (schizophrenic patients were excluded) maintained cessation at 1 year: female gender and prematurely interrupted follow-up were significantly associated with the risk of relapse at 1 year.

With regard to smoker healthcare professionals, a meta-analysis published in 2020 of ten studies (6 cohort studies and 4 clinical trials) measured a one-year cessation rate of 21% following the application of pharmacological or behavioural interventions. Hajek et al. showed in a randomised trial that the vaporiser could double the success rate at 1 year compared with treatment with nicotine replacement therapy alone, if accompanied by behavioural support.

Invesigators therefore believe it is possible to achieve a one-year cessation rate of 30% with workplace consultations combining support, nicotine replacement therapy and/or a vapour device where appropriate.

Doctors' smoking status and attitudes towards smoking are known to influence their enthusiasm for advising their patients against smoking.

As the Nagahapitye et al. study made clear: 'It is reasonable to assume that a healthcare professional who is not a smoker or is a former smoker will be more committed and more convincing in spreading messages about smoking and cessation. Health professionals smoking habits are therefore an important factor in the prevention of tobacco-related diseases.

The hypotheses of PSYTaB are :

  • To improve cessation and reduction rates among smokers working in mental health,
  • To improve the management of their patients' smoking and representations of smoking.

This study may also highlight benefits for the healthcare establishment and society, notably in terms of reduction in sick leave rates.

This study involves no risk for the subject.

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • Smoking Cessation
  • Smoking consultation
  • carbon monoxyde measurement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Health professional
  3. Daily smoker of at least 1 cigarette or joint per day and every day
  4. Willingness to quit smoking
  5. Patient physically able and willing to undertake a carbon monoxyde measurement
  6. Patient affiliated to a social security scheme or beneficiary of such a scheme
  7. Signature of

Exclusion criteria

Exclusion Criteria:

  1. Smoking via vaporizer exclusively
  2. Occasional (i.e. not daily) smoker or exhaled carbon monoxyde at inclusion \< 9 ppm
  3. Resignation, transfer or end of employment contract during the study period (1 year)
  4. Unable to undergo study follow-up for geographical, social or psychological reasons
  5. Persons under legal protection or unable to express their consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    consultation tabacco

    At the first T0 consultation, the tobacco nurse : * Carries out a monoxyde carbon measurement, In order to assess the patient's smoking profile and find out their degree of nicotine dependency, what might be holding them back from quitting, what might be motivating them, their psychological state, their fears and their medical history. * Define a programme for smoking cessation : the planned date for cessation, the treatment chosen, any additional specific therapy or consultations, and the date of the next appointments. During the 6-month follow-up sessions, the nurse assesses the patient's mood and anxiety, with a view to adapting the treatment if necessary. At the final consultation at T12 months, the nurse assesses the patient's withdrawal and the effect of the follow-up tobacco consultations.

    Diagnostic Test: exhaled carbon monoxyde measurement

Interventions

  • Diagnostic testexhaled carbon monoxyde measurement

    At the initial tobacco consultation: measurement of exhaled carbon monoxyde. At the tobaccology consultation at 12 months, measurement of the cessation rate: no tobacco smoked in the last 7 days (self-reported), confirmed by a measurement of exhaled carbon monoxyde \< 9 ppm.

06

What researchers measure

Primary outcomes

  1. Evalue the effectiveness of a counseling consultation in the workplace among smoker health professionals.

    Cessation rate at 12 months: At the 12-month visit, no smoking in the last 7 days (self-reported) confirmed by a measurement of exhaled carbon monoxyde \< 9 ppm.

    Time frame: At 12 month

Secondary outcomes

  1. Prevalence of anxiety and depressive disorders

    Mean Hospital Anxiety and Depression Scale scores To screen for anxiety and depressive symptoms, the following interpretation can be proposed for each of the scores (A and D) Total Score \[0;21\] * 7 or less: no symptoms * 8 to 10: doubtful symptomatology * 11 or more: definite symptomatology

    Time frame: at inclusion

  2. Prevalence of chronic pain

    Pain numerical scale \> 3/10 for 3 months or more

    Time frame: at inclusion

  3. Prevalence of chronic fatigue

    Pichot scale, cut-off = 22

    Time frame: at inclusion

  4. Effectiveness of counseling consultation on anxiety and depressive disorders

    Mean Hospital Anxiety and Depression Scale scores To screen for anxiety and depressive symptoms, the following interpretation can be proposed for each of the scores (A and D), Total score \[0;21\] * 7 or less: no symptoms * 8 to 10: doubtful symptomatology * 11 or more: definite symptomatology

    Time frame: at inclusion, 6 months and 12 months

  5. Effectiveness of counseling consultation on pain

    Mean Pain Numerical Scale in the last 24 hours. Numerical scale from 0 to 10. Note 0 corresponds to "no pain". Note 10 corresponds to "maximum imaginable pain".

    Time frame: at inclusion, 6 months and 12 months

  6. Effectiveness of counseling consultation on chronic fatigue

    Pichot scale score Total Score \[0; 32\] A total \> 22 indicates excessive fatigue

    Time frame: at inclusion, 6 months and 12 months

  7. Effectiveness of counseling consultation on the sense of personal efficacy with consumption and management of patients' smoking habits

    Numerical scale from 0 to 10 (0 means 'I'm absolutely sure I won't make it' and 10 means 'I'm absolutely sure I'll make it')

    Time frame: at inclusion , 12 months.

  8. Effectiveness of counseling consultation on use of ancillary products

    Rate of subjects using ancillary products and search for other uses and intentions (cessation or reduction)

    Time frame: at inclusion, 12 months

  9. Medico-economic impact of counseling consultation

    Number of sick leave days

    Time frame: between inclusion and 12-month follow-up

  10. Prevalence of burnouts

    Maslach scale score The questionnaire thus yields 3 scores: * Professional Exhaustion Score (SEP) Total Score \[0;54\] A SEP \< 17 reflects a low degree of burnout. A SEP between 18 and 29 indicates a moderate degree of burnout. A SEP over 30 indicates a high degree of burnout (red zone). * Depersonalization/Loss of Empathy Score (SD) Total Score \[0;30\] An SD \< 5 reflects a low degree of depersonalization. An SD between 6 and 11 indicates a moderate degree of depersonalization. An SD greater than 12 indicates a high degree of loss of empathy (red zone). * Personal Accomplishment Score (SAP). Total Score \[0;48\] A SAP \< 33 reflects a low degree of personal fulfillment (red zone). An SAP between 34 and 39 reflects a moderate degree of personal fulfillment. An SAP above 40 indicates a high degree of personal fulfillment. If both SAP and SD scores are in the red, the risk of Burn-out is very high, especially if the degree of personal fulfillment is also in the red.

    Time frame: at inclusion

  11. Determine the profile of the smoker health professionals

    Data collection: gender, age, profession; level of dependence (Fagerstrom score); level of motivation to smoke and to use cannabis, if applicable (Richmond scale); and level of confidence in managing their patients' tobacco dependence.

    Time frame: at inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 24 months is close to that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 25, 2025
StartActual
Nov 11, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06988644
Lead sponsor
Groupe Hospitalier Mutualiste de Grenoble
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Nov 11, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 29, 2025

Study contacts

Estelle Cotte-Raffour, Nursery
Contact
estelle.cotte-raffour@avec.fr
0033 476708995
Laurence Fabaron, Nursery
Contact
lfabaron@ch-alpes-isere.fr
0033 4 76 56 48 37
Olivier Jenny, Medical doctor
study chair · Hospital Center Alpes-Isère

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion